Dr Lindsay Rosenwald | Lindsay Rosenwald Success & Achievements

Today, the biotechnology industry is evolving rather quickly and Dr. Lindsay Rosenwald plays a key role in its growth.  Dr. Rosenwald has invested in a long and diverse list of companies, including research centers and companies developing new drugs.

Dr. Lindsay Rosenwald has gained a respectable standing on Wall Street where he is a venture capitalist and hedge fund manager.  For almost two decades he has also been building an uncompromising reputation in life-sciences and medicine research.  He has always played a key role in R&D breakthroughs in biotechnology and healthcare.  As a result of the way he combines medicine with finance, Dr. Rosenwald has the expertise to both launch new initiatives in research as well as locate ideal companies to invest in.  His work has helped to extend the reaches of healthcare, indirectly benefiting millions of people the world over.  It would be difficult to find another individual who has excelled as well as he in these industries.

During his stunning career, almost two decades long, Dr. Lindsay A. Rosenwald is responsible for creating and recapitalizing numerous public and private companies in the life-science and biotech industries.

Rosenwald finished his high school education in 1973 at Abington.  Thereafter, he attended Pennsylvania State University, graduating with a degree in Finance.  After Penn State, he received his medical degree from the Temple University School of Medicine and went on to meet the requirements of his medical internship at Abington Medical Hospital.  For a short while he had his own private medical practice before moving on to other things.  He carved his way successfully through Wall Street, combining his knowledge in both medicine and finance to form new ideas.

Between the years of 1994 and 2007, Rosenwald took on the role of executive director at the Aries Funds which has invested more than $1 billion into healthcare companies that show promise.  Rosenwald also directed the Orion Fund from 2002 to 2006, which invested only in the biotech industry, especially private investments in public equity.

Dr. Rosenwald also created the Rosenwald Foundation, a non-profit that is committed to supporting scientific, healthcare and educational companies.

A unique mixture of finance and medicine has led Rosenwald down a path of discovery in the medicine, biotechnology and life sciences industries, where he has had the opportunity to explore new and innovative projects.

Today Dr. Rosenwald is a director at the Republican Jewish Coalition.  He is also the president of Paramount Group which concentrates its efforts on investment banking, R&D, and equity management in the industries of life-science and biotechnology.  One of his most recent enterprises is the OpusPoint Partners, LLC, established in 2009 with the purpose of supporting innovations in life-sciences and biotechnology.  The company is dedicated to technological breakthroughs that will influence and guide today’s life-sciences and biotechnology companies.

Some of Dr. Lindsay Rosenwald and his team’s most admirable accomplishments include the funding they have offered various companies and drug candidates showing great promise.   One such company is Cougar Biotechnology Inc., based in L.A., which focuses on cancer treatment.  One of the company’s recent developments was Abiraterone, a drug that tackles aggressive prostate cancer.  The company was sold to Johnson & Johnson for almost $1 billion in 2009 after a negotiation with Dr. Rosenwald.

It is the mandate of OpusPoint Partners and Dr. Rosenwald to continue making progress with projects like these.  With their work they intend to profoundly alter the fields of medicine and the life sciences, while giving hope to millions of people across the globe.

By creating solid relationships and building upon their past experience, Dr. Rosenwald and OpusPoint Partners will pave the way to a bright future.  They blaze ahead leaving a trail of revolutionary successes.  Dr. Rosenwald is a true leader in healthcare and biotechnology.  He has a number of firsts to his name.  He was the first to put an investment into the first obesity drug in the US market.  He was also the first to start the first stem cell company that deals with public trading.  In addition, the first public gene therapy company developed with his contribution and so did the first cancer vaccine available to the public.

The present aim for Dr. Lindsay Rosenwald and OpusPoint Partners is to create a solid network with other leaders that espouse the same values and business approaches and who are dedicating to discovering and investing in ground-breaking technologies across these fields.

With this kind of commitment, strategy and expert knowledge, OpusPoint Partners and its founders, Dr. Rosenwald and Michael S. Weiss, have a brilliant and steady path lying ahead of them.  Their investments have the ability to completely alter the way in which we manage disease.

OpusPoint Partners envisions a world with greater commitment to better medicine and healthcare.  They intend to be at the forefront of this new wave of revolutionized healthcare by making strong investments of time and money in the newest innovations.  With the progressive development of life science and healthcare, mankind will achieve a brighter future that is healthier for everyone.

OpusPoint Partners, founded in 2009, is only one of the biotech companies established by Michael S. Weiss and Dr. Lindsay Rosenwald.  The two men have over 40 years of experience between them in life sciences and biotech investment.  They both have a strong passion for the field of biotechnology.

Cougar Biotechnology Inc. is another company founded by Dr. Lindsay Rosenwald.  The company is based in Los Angeles and focuses on experimental drug research for cancer.  Cougar has gained some attention from researchers and investors impressed by some of its more remarkable developments of experimental drugs.   One such drug has shown promise in the treatment of late-stage prostate cancer.  For about one billion dollars, Cougar Biotech Labs was acquired by Johnson & Johnson on July 10, 2009.

OpusPoint Partners and Lindsay Rosenwald are committed to maintaining strong business associations with the biotechnology and investment communities. Practicing integrity is imperative to this goal by remaining transparent and practicing honest investment.  When companies and leaders of the industry all respect these values for good business and organization, strong alliances can be formed.

OpusPoint Partners is creating relationships with several researchers, investors and corporations that have the same goals while helping new companies to meet their priority goals.  These partnerships are part of the larger aim to offer the world new innovations that will affect how diseases are diagnosed and treated.  Along with this team, Dr. Lindsay Rosenwald and OpusPoint Partners will seek out and invest in companies promising breakthrough medical research.

Dr. Lindsay Rosenwald and OpusPoint Partners are really pushing the boundaries of biotech investing.  They are changing and improving the standards of investing.  The advice they give to biotechnical facilities is to apply well-rounded business practices and a strong set of principles.  With these applications, companies can benefit from gaining high returns without high risks.  The success of OpusPoint Partners proves that this formula works.

And Dr. Rosenwald is not new to success.  He has had a wealth of experience.  He has had over 17 years on Wall Street as a biotechnology entrepreneur.  He has also played a big role in the founding and recapitalization of several biotech and life sciences companies, both public and private.  He holds a B.S. in Finance from Pennsylvania State University and an M.D. from the Temple University School of Medicine.

He also has solid financial experience managing billions of dollars in funds.  He managed the Aries Funds from 1994 to 2007 and the Orion Fund from 2002 to 2006.  The Aries Funds have invested more than $1 billion in healthcare.  The Orion Fund, on the other hand, is completely for private biotechnology investing, particularly PIPEs.

OpusPoint Partners is founded upon a bold mission – to establish a strong network of life science and healthcare groups that are committed to honesty and integrity.  This is a rarity in today’s world where business leaders often disregard ethics in order to get desired clinical trial results and more profit.

OpusPoint Partners intends to be a diversion from that commonality.  The company has shown a great deal of integrity in dealings with shareholders, investors and employees.  And a valued approach of ethical standards is used in handling the matters of testing, manufacturing and investigating drugs.

Under Michael Weiss and Dr. Lindsay Rosenwald’s leadership, OpusPoint Partners has a promising future.  With the shared experience and knowledge both leaders possess, the company is bound to play a crucial role in revolutionizing medicine and healthcare.

It is difficult, though, to change practices that have been the basis of medical approaches for years.  It will take money, time, energy and strong commitment to keep within the guiding lines of ethics and to resist going to any means just to reap more profits.

Dr. Rosenwald, however, thinks this can be done.  As an example, he points out the achievements the company has already made.  Over the last several years, OpusPoint Partners has already surpassed projected goals while they assisted the financing of over 20 companies.  Using the best kind of practices and processes will most certainly yield rewards in drug research and finance.

Dr. Lindsay Rosenwald serves on the Board of Directors of the Republican Jewish Coalition.  He has also made strong connections with industry leaders from the biotechnology financing sector.  OpusPoint Partners looks forward to a successful future under his leadership.

OpusPoint Partners is getting ready for new and innovative growth in the fields of life science and healthcare. This growth will see a revolutionized approach to medicine and healthcare, improving the quality of living for everyone. OpusPoint Partners will be a leader in this movement, by investing time and money into groundbreaking approaches. They see life in a better world.

OpusPoint Partners was created by Michael S. Weiss and Dr. Lindsay Rosenwald. Established in 2009, it is just one of a few companies the men have founded together devoted to the field of biotechnology. With 40 years of experience between them, Weiss and Rosenwald continue to express their love for biotechnology with biotech investment and life sciences.

Dr. Lindsay Rosenwald also created Cougar Biotechnology Inc., a company that researches experimental drugs for the treatment of cancer. The Los Angeles-based company has gained a certain reputation with the development of some promising drugs. One drug shows very good potential to help treat the late states of prostate cancer. On July 10, 2009, Cougar Biotech Labs was bought by Johnson & Johnson for about a billion dollars.

OpusPoint Partners and Lindsay Rosenwald are keen about developing strong investment and biotechnology relationships. This can be achieved by practicing integrity in relations (marked by being direct and straightforward and by investing honestly). This is not only good business ethics but is essential to the culture of an organization. When all the companies and industry leaders in partnership share in the same values, it makes their bonds more meaningful.

Lindsay Rosenwald and OpusPoint Partners are aligning with several entities – a team of individuals, researchers, investors and corporations – with the same commitments to innovative disease treatment. This alignment will also assist emerging companies in accomplishing their most important aims. With these relationships, Dr. Lindsay Rosenwald and OpusPoint Partners will locate and invest in companies doing the research on the verge of important medical discoveries.

Dr. Lindsay Rosenwald and OpusPoint Partners are pushing the limits of the biotech investment industry by asking companies to raise their current standards. Assuming higher standards of ethical approach and responsibility will allow companies to continue to earn profit without reducing the quality of production, results and other potential risks. The company’s successes have proven the effectiveness of this.

And Dr. Rosenwald is no stranger to applying successful models. He has been proactively involved in establishing and recapitalizing biotech and life sciences companies, both public and private. In addition he has spent more than 17 years as a Wall Street biotechnology entrepreneur. He obtained a B.S. in Finance from Pennsylvania State University and an M.D. from the Temple University School of Medicine.

He has also managed a variety of large investment funds. The Aries Funds, under his management from 1994 to 2007, invested more than $1 billion towards healthcare. The Orion Fund, which he managed from 2002 to 2006, is entirely geared towards private biotechnology investments, principally PIPEs.

OpusPoint Partners’ aim is to form a powerful group of connections in life science and healthcare that will uphold strong moral principles. This kind of establishment is a rare incidence in today’s money-making world. It is all too common that business leaders make choices for profit without considering their ethical implications.

OpusPoint Partners aims to go against the grain. It stands strongly committed to maintaining high ethical principles in the testing, manufacturing and investigating of drugs. It will also practice fairness and responsibility in relations with its business partners.

The future of OpusPoint Partners looks exceedingly bright under the direction of Michael Weiss and Dr. Lindsay Rosenwald. The two highly experienced leaders both know that they have a lot to offer in changing the face of medical treatment and diagnosis.

However, changing what has been steeped in years of practice cannot be easy. The process will require a great deal of devoted time, money and real dedication in order to maintain ethical commitments.

Dr. Rosenwald believes this can be achieved. In less than two years, OpusPoint Partners helped to finance more than 20 companies, reaching beyond its slated goals, a prime example of how change can happen. With the use of the right kinds of practices and processes, large returns in drug research and finance are inevitable.

Dr. Lindsay Rosenwald represents the Republican Jewish Coalition as a member of the Board of Directors. He also has several important affiliations with biotechnology industry leaders in the financing sector. OpusPoint Partners is bound to have a successful future with Dr. Rosenwald as its leader.